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Resistance of Bcr-Abl-positive leukemic stem cells (LSCs) to imatinib treatment in patients with chronic
myeloid leukemia (CML) can cause relapse of disease and might be the origin for emerging drug-resistant
clones. In this study, we identified Smo as a drug target in Bcr-Abl-positive LSCs. We show that Hedgehog
signaling is activated in LSCs through upregulation of Smo. While Smo/ does not impact long-term recon-
stitution of regular hematopoiesis, the development of retransplantable Bcr-Abl-positive leukemias was
abolished in the absence of Smo expression. Pharmacological Smo inhibition reduced LSCs in vivo and en-
hanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective
treatment strategy to reduce the LSC pool in CML.INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disease that origi-
nates from a single transformed hematopoietic stem cell (HSC)
or multipotent progenitor cell harboring the Philadelphia translo-
cation t(9;22) (Maguer-Satta et al., 1996; Nowell, 1962). The
expression of the resulting gene product, Bcr-Abl, induces
molecular changes that result in the expansion of malignant he-
matopoiesis, including the leukemic stem cell (LSC) pool, and
the suppression of nonmalignant hematopoiesis (Nowell, 1962;
Stam et al., 1987). Myeloid cells (granulocytes, monocytes,
megakaryocytes, and erythrocytes) but also B and T cells ex-
press Bcr-Abl, pointing toward the multipotent progenitor cell
or HSC as the initiating cell of the disease (Fialkow et al., 1978;
Takahashi et al., 1998). In contrast to oncogenes causing acute
myeloid leukemia, such as Moz-Tif2 or Mll-Enl, Bcr-Abl cannot
confer self-renewal properties to committed progenitor cells
(Cozzio et al., 2003; Huntly et al., 2004) but rather utilizes and en-
hances the self-renewal properties of existing self-renewing238 Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Incells. During the course of the disease, the LSC pool expands,
and in the final stage, the blast crisis, the majority of CD34+
stem and progenitor cells carry the Philadelphia translocation
(Holyoake et al., 1999; Maguer-Satta et al., 1996). Recent publi-
cations suggest that developmental pathways like the Wnt sig-
naling pathway or the Polycomb-group protein Bmi1 might be in-
volved in the regulation and expansion of LSCs during CML blast
crisis (Hosen et al., 2007; Mohty et al., 2007; Muller-Tidow et al.,
2004; Xie et al., 1998). In contrast to blast crisis, we have only
limited knowledge about the mechanisms involved in the initial
expansion of the Bcr-Abl-positive LSCs during the chronic
phase of the disease.
The Hedgehog (Hh) signaling pathway is a developmental
pathway that has been shown to play a role in primitive and adult
hematopoiesis (Byrd et al., 2002; Chiang et al., 1996; Trowbridge
et al., 2006). Hedgehog ligands (Sonic hedgehog [Shh], Indian
hedgehog [Ihh], and Desert hedgehog [Dhh]) produced by
stroma cells bind to the seven-transmembrane domain receptor
Patched (Ptch). Ligand binding to Ptch releases Ptch binding toSIGNIFICANCE
The Abl inhibitor imatinib induces hematologic remissions in the majority of chronic myeloid leukemia (CML) patients, but
failure to eradicate the leukemic stemcells (LSCs) can induce relapse of disease after end of treatment and forces patients to
undergo lifelong therapy. Therefore, development of drugs that specifically target the LSC pool in CML is essential to cure
this disease. Our findings indicate that Smo, which is specifically upregulated in Bcr-Abl-positive cells andwhich is essential
for the expansion of the LSC pool, might be one of those targets while sparing normal hematopoietic stem cells. These re-
sults indicate that Smo is a specific and druggable target for Bcr-Abl-positive LSCs and that Smo inhibition in CML patients
might be a step toward eventually eliminating the disease.c.
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This results in a conformational change of Smo and subsequent
activation of the downstream signaling pathway leading to
induction of the Gli transcription factors (Gli1, Gli2, and Gli3)
and transcription of target genes like Gli1, Ptch1, cyclin D1, and
Bcl2 (Duman-Scheel et al., 2002; Lee et al., 1997; Marigo and
Tabin, 1996).
Hematopoiesis in vertebrate embryos occurs in two waves, in-
cluding the primitive embryonic first wave resulting in primitive
erythrocytes and the second, definitive or adult wave that gener-
ates HSCs that maintain hematopoiesis throughout adult life.
Primitive and definitive hematopoiesis of the frog embryo stem
from different blastomeres of the 32-cell-stage embryo, indicat-
ing important differences in molecular programming during em-
bryogenesis (Ciau-Uitz et al., 2000). Murine explants and embry-
onic stem (ES) cell studies have suggested a role for Hh signaling
in primitive hematopoiesis. During early embryogenesis, secre-
tion of Ihh by visceral endoderm has been shown to be essential
for the formation of primitive hematopoietic cells in the yolk sac
of murine embryos (Dyer et al., 2001), and embryoid bodies dif-
ferentiated in vitro from ES cells that lack Ihh or Smo fail to form
hematopoietic cells (Byrd et al., 2002; Maye et al., 2000). In con-
trast, zebrafish embryos with defective mutations in Hh pathway
members or treated with the Hh inhibitor cyclopamine display
defects in adult HSC formation, but not in the generation of prim-
itive hematopoiesis (Gering and Patient, 2005). Finally, targeted
deletion of Shh (Chiang et al., 1996), Ihh (Byrd et al., 2002), or
Dhh (Bitgood et al., 1996) in mice has failed to provide convincing
evidence for a role of Hh in hematopoiesis at all. These conflict-
ing results might be due to functional redundancy of the different
Hh proteins in mammals and could not be clarified accordingly
due to the embryonic lethality of Smo/ embryos in midgesta-
tion. Furthermore, there are significant functional differences
between defined HSC and progenitor populations of different
species (mouse, human, and zebrafish), which are probably
due to huge variations in life spans and the resulting diverging
needs for maintenance of HSCs.
The development of the Abl kinase inhibitor imatinib was
a breakthrough in the therapy of chronic-phase CML. In a 5
year follow-up study (Druker et al., 2006), the authors demon-
strated complete hematological response in 98% of the treated
patients, a complete cytogenetic response in 87%, and a com-
plete molecular response in about 35%. Relapse rates during
continuous treatment were 17%, and discontinuation of treat-
ment due to side effects occurred in 4% of the cases. Despite
this great success, several reports indicate that discontinuation
of imatinib treatment even in patients who have already achieved
molecular response induces a relapse of the disease (Rousselot
et al., 2007; Breccia et al., 2006; Mauro et al., 2004; Merante
et al., 2005; Cortes et al., 2004), and therefore, patients are
forced to undergo lifelong therapy. Further studies have demon-
strated that imatinib effectively eradicates Bcr-Abl-positive pro-
genitor cells but does not target Bcr-Abl-positive CD34+ LSCs
(Graham et al., 2002; Jiang et al., 2007). While new inhibitors
(nilotinib and dasatinib) that target primary imatinib-resistant
Abl mutants provide treatment options for relapsed patients or
patients in blast-crisis CML, these Abl inhibitors also do not tar-
get the LSCs in CML (Copland et al., 2006; Jorgensen et al.,
2007). Therefore, it is intriguing to postulate that therapies spe-Cacifically targeting the LSCs will add additional therapeutic op-
tions in CML to prevent relapse of disease after discontinuation
of treatment and to prevent the expansion of imatinib-resistant
LSC clones during continuous treatment.
Therefore, the aim of our study was to examine the role of the
Hedgehog signaling pathway in normal and malignant hematopoi-
esis and to define Smo as a specific drug target for LSCs in CML.
RESULTS
The Hedgehog Signaling Pathway Is Activated in Bcr-
Abl-Positive Leukemic Stem Cells and Differentiated
Hematopoietic Cells via Upregulation of Smo
To evaluate the activation status of the Hedgehog signaling path-
way in Bcr-Abl-positive LSCs versus normal HSCs, we com-
pared the transcript levels of two Hh pathway target genes,
Gli1 and Ptch1, in human CD34+ cells from healthy donors ver-
sus CD34+ cells isolated from patients with CML in chronic
phase or blast crisis (see Table S1 available online). In all CML
cases, we observed a greater than 4-fold induction of transcript
levels for Gli1 and Ptch1, indicating activation of the pathway as
early as in chronic phase (Figure 1A). To further evaluate the role
of Hh pathway activation in Bcr-Abl-driven leukemia, we induced
a CML-like syndrome in mice (Daley et al., 1990; Heisterkamp
et al., 1990). Bone marrow infected with a pMSCV/Bcr-Abl/
IRES-GFP virus was transplanted into irradiated recipient mice,
and mice developed a CML-like syndrome within 2 weeks after
transplantation. Bcr-Abl-positive LSCs (LinKit+Sca+GFP+)
obtained from diseased mice displayed enhanced Gli1 and
Ptch1 transcript levels compared to normal mouse HSCs (Lin
Kit+Sca+), reconfirming our findings from human patient sam-
ples (Figure 1A). Elevated Gli1 and Ptch1 expression in mouse
bone marrow infected with a Bcr-Abl retrovirus was not
restricted to the stem cell population alone but was present in
all Bcr-Abl-overexpressing cells (Figure 1B).
Several mechanisms have been described that lead to the
activation of the Hh signaling pathway in tumor cells. Activating
point mutations of Smo or inactivating point mutations in Ptch1
or SUFU have been detected in sporadic basal cell carcinoma
(Aszterbaum et al., 1999; Oro et al., 1997; Xie et al., 1998), medul-
loblastoma (Goodrich and Scott, 1998; Marino, 2005), and rhab-
domyosarcoma (Tostar et al., 2006). We have recently shown
that activation of Hh signaling in lymphoma cells occurs via pro-
duction of Hh ligands from infiltrating dendritic cells and mesen-
chymal stem cells (Dierks et al., 2007). Other tumors, like pancre-
atic cancer and small-cell lung cancer, were described to be
dependent on Hh signaling via autocrine activation loops (Ber-
man et al., 2003; Watkins et al., 2003). In contrast to the mecha-
nisms described before, we detected an upregulation of the
transmembrane receptor Smo in all pMSCV/Bcr-Abl/GFP-posi-
tive bone marrow cells compared to regular hematopoiesis in
the same mice. The upregulation of Smo in the Bcr-Abl-positive
population could be detected by quantitative PCR (Figure S1)
and flow cytometry (Figure 1C) as well as immunohistochemistry
(IHC). IHC stainings from spleens and bone marrow of diseased
mice with a Smo-specific antibody showed a strong induction of
Smo expression in the infiltrating Bcr-Abl-positive population
(Figure 1D). IHC stainings for Smo and Gli1 in human CML cases
also revealed upregulation of both proteins in correspondingncer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc. 239
Cancer Cell
Smo Is Essential for Leukemic Stem Cells in CMLFigure 1. Bcr-Abl Activates Hedgehog Signaling in Bone Marrow by Upregulation of Smo in Hematopoietic Stem Cells and Differentiated
Cells
(A) Transcript levels for Gli1 and Ptch1 in purified CD34+ cells from healthy donors and patients with CML in the chronic or blast crisis phase. Values are
normalized to CD34+ cells from healthy donors. n = 3, ±SD.
(B) Expression of Gli1 and Ptch1 transcript levels in Bcr-Abl-positive versus -negative whole bone marrow and stem cells in mice. n = 3, ±SD.
(C) Flow cytometric analysis of anti-Smo-PE antibody binding to Bcr-Abl-positive versus -negative bone marrow cells.
(D) Immunohistochemical (IHC) staining for Smo in bone marrow and spleen infiltrated with Bcr-Abl-positive leukemic cells (arrow indicates micromegakaryo-
cytes typical of Bcr-Abl-positive bone marrow). Scale bars = 100 mM.
(E) IHC staining for Smo and Gli1 expression in bone marrow from human CML. Scale bars = 100 mM.regions of the bone marrow, especially in the blast cell popula-
tion (Figure 1E). Abl inhibition in murine Bcr-Abl-positive bone
marrow cultures using imatinib and nilotinib decreased Smo
and Gli1 transcript levels by only 20% (Figure S2), indicating
that Smo upregulation is to a significant part independent of
Abl kinase activity and that other mechanisms account for the in-
creased expression of Smo in the Bcr-Abl-positive population.
We have recently shown that retroviral expression of Smo in
lymphoma cells facilitates the growth of Em-Myc-positive
lymphoma xenografts in nonlymphoid organs like the skin and
enhances Gli1 levels even in the absence of ligand stimulation240 Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc(Dierks et al., 2007). Therefore, upregulation of Smo in Bcr-Abl-
positive bone marrow cells may reveal an additional mechanism
of Hh pathway activation in malignancies and can induce consti-
tutive Hh signaling or at least hyperresponsiveness to Hh ligand
stimulation in the Bcr-Abl-positive population.
Inhibition of Hedgehog Signaling In Vitro Induces
Apoptosis in Bcr-Abl-Positive Cells and Reduces
the Number of Leukemic Stem Cells
To further validate the importance of the Hh pathway in Bcr-Abl-
positive bone marrow cells and LSCs in vitro, we inhibited Hh.
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Smo Is Essential for Leukemic Stem Cells in CMLFigure 2. Inhibition of Hedgehog Signaling In Vitro Induces Apoptosis in Bcr-Abl-Positive Cells and Reduces the Number of Leukemic
Stem Cells
(A) Flow cytometric analysis of GFP-positive cells after in vitro treatment with either DMSO or cyclopamine (2 mM and 5 mM) for 72 hr.
(B) Percentage of Bcr-Abl (GFP)-positive myeloid progenitors (LinKit+Sca) and leukemic stem cells (LinKit+Sca+) after treatment of mixed bone marrow
cultures with cyclopamine for 72 hr in three independent experiments ±SD.
(C) Annexin V staining of Bcr-Abl (GFP)-positive cell cultures after treatment with cyclopamine for 48 hr.
(D) Cell-cycle distribution of gated viable cells after treatment with cyclopamine for 24 hr in Bcr-Abl-positive bone marrow and stem cells.
(E) Colony assays from mixed bone marrow cultures (Bcr-Abl-positive and -negative) in methylcellulose medium without cytokines after 72 hr treatment with
cyclopamine.
(F) Total number of colonies counted 10 days after plating of cyclopamine-treated mixed bone marrow cultures.signaling using KAAD-cyclopamine (Chen et al., 2002), an alka-
loid, which locks Smo in its inactive conformation. We used
bone marrow from mice with CML-like syndrome that contained
about 50% Bcr-Abl/GFP-positive cells versus 50% regular bone
marrow cells. Cyclopamine treatment of these mixed bone mar-
row cultures for 3 days resulted in a dose-dependent reduction
of the Bcr-Abl/GFP-positive population compared to the GFP-
negative population (Figure 2A). Further characterization of the
different cell subsets demonstrated a reduction of the Bcr-Abl-
positive myeloid progenitor cells (LinKit+Sca) by more than
80% and a reduction of the LinKit+Sca+ LSC population by
around 70% (Figure 2B). The predominant effect of cyclopamine
treatment on Bcr-Abl-positive bone marrow cells was apoptosisCainduction within 48 hr (Figure 2C) as assessed by annexin V
staining. We also detected alterations in the cell cycle, with a rel-
ative increase of the G1 phase compared to the S phase and G2
phase in the complete bone marrow (Figure 2D, upper panel).
Cell-cycle analysis of the LSC population showed a complete
loss of the G2 phase in these cells after Hh pathway inhibition
(Figure 2D, lower panel).Gli1 transcript levels in the bone marrow
were reduced after treatment with cyclopamine, verifying the
inhibition of the Hh signaling pathway in these cells by the
compound (Figure S3).
To further validate the effect of Hh pathway inhibition on the
self-renewing progenitor and LSC populations, we treated mixed
bone marrow and spleen cultures with different concentrationsncer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc. 241
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then plated the cells on methylcellulose plates without supple-
mentary cytokines, so that only Bcr-Abl-positive cells could sur-
vive. Colonies were counted 10 days after plating. Bone marrow
and spleen cultures pretreated with cyclopamine showed
a dose-dependent reduction of Bcr-Abl-positive colonies, indi-
cating that the colony-forming Bcr-Abl-positive cells are depen-
dent on Hh pathway activation (Figures 2E and 2F) (1 out of 3
examples).
Self-Renewal Capacity of Regular Short-Term
Repopulating HSCs and T Cell Development
Are Dependent on the Status of Hedgehog
Pathway Activation
The role of Hh signaling in normal hematopoiesis is not com-
pletely understood, but several publications indicate that Hh sig-
naling plays a role in adult hematopoiesis (Dyer et al., 2001; Ger-
ing and Patient, 2005; Trowbridge et al., 2006). Overexpression
of Ihh in bone marrow stroma cells enhances hematopoietic
regeneration after transplantation (Kobune et al., 2004), and
Ptch1+/ mice have a higher regeneration potential of short-
term repopulating HSCs (Trowbridge et al., 2006). Due to the em-
bryonic lethality of Smo/mice, the effect of loss of Hh signaling
in normal hematopoiesis in mice is not well established, although
a distinct knowledge is essential to define risks that could
be caused by Smo inhibitors, which are currently being explored
for the treatment of solid tumors with mutations in the Hh
pathway (medulloblastoma, rhabdomyosarcoma, and basal
cell carcinoma).
To bypass this problem, we used fetal HSCs isolated from the
liver of embryos at day 14.5 of the gestation period. Fetal liver
cells from Smo/, Smo+/, Smo+/+, Ptch1+/+, and Ptch1+/ em-
bryos were analyzed regarding the number of fetal HSCs, num-
ber of differentiated hematopoietic cell types, colony-forming
capacity, and repopulation potential in a transplantation experi-
ment. We detected no differences in the number of fetal HSCs
between the different genotypes and also no significant differ-
ences in numbers of B cells (B220), myeloid cells (CD11b), ery-
throid progenitors (Ter119), or CD3+ T cells (Table S2). Plating
of fetal liver cells into methylcellulose agar with supplementary
cytokines (IL-3, IL-6, and SCF) did not result in any differences
in the number of colonies, in the colony types, or in the percent-
age of different cell types as measured by flow cytometry
10 days after plating (Table 1 and data not shown). In contrast
to the first plating round, we observed significant differences in
the colony-forming potentials after replating for a second round.
While replated Ptch1 and Smo wild-type (WT) hematopoietic
cells showed only very limited colony-forming potential in the
Table 1. Colony Numbers 10 Days after Plating of Fetal Liver
Cells
Genotype P1 P2 P3
Smo/ 130 0 0
Smo+/ 142 0 0
Smo+/+ 121 2 0
Ptch1+/+ 128 3 0
Ptch1+/ 136 48 23
P = plating round.242 Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Insecond plating round and Smo/ hematopoietic cells had lost
colony-forming potential completely, Ptch1+/ hematopoietic
cells kept their ability to form colonies over more than three plat-
ing rounds, indicating that Hh pathway activation enhances the
number of regenerating cells and self-renewal properties of
Ptch1+/ hematopoietic bone marrow (Figure 3C; Table 1).
In a second experiment, we transplanted Smo/, Smo+/,
Smo+/+, Ptch1+/+, and Ptch1+/ fetal liver cells (positive for Ly5.2)
into sublethally irradiated C57BL/6-Ly5.1-Pep3b mice (B6-Ly5.1
Smo/, B6-Ly5.1 Smo+/, B6-Ly5.1 Smo+/+, B6-Ly5.1 Ptch1+/+,
and B6-Ly5.1Ptch1+/). The regeneration of Ly5.2-positive hema-
topoiesis in the peripheral blood showed a significant advantage
for mice transplanted with Ptch1+/ fetal liver cells compared to
mice transplantedwith fetal liver cells isolated fromthe other geno-
types. The number of Ptch1+/ Ly5.2-positive cells in the periph-
eral blood was about double compared to WT and Smo/ cells
over a period of more than 3 months (Figure 3D). The regeneration
of Smo/ bone marrow 2 months after transplantation was not
significantly different from WT bone marrow, indicating that there
are no differences in the long-term regeneration capacity of
Smo/ versus Smo WT HSCs. However, further analysis of the
cell types in the peripheral blood showed differences in the distri-
bution of cells between mice transplanted with Smo/ versus
Smo WT fetal liver cells. B6-Ly5.1 Smo/ showed a greater
than 90% decrease in CD8+ T cells, and the number of CD4+
T cells was decreased by 30%. These results confirm recent find-
ings that Hh signaling is important for T cell development (El Anda-
loussi et al., 2006; Uhmann et al., 2007), and our results indicate
especially that the generation of CD8+ T cells is dependent on
intact Hh signaling (Figure 3E).
To further establish the role of Hh signaling in HSCs, we chal-
lenged the hematopoietic regeneration capacity of B6-Ly5.1
mice that had been transplanted with Ly5.2-positive Smo/,
Smo+/,Smo+/+,Ptch1+/+, orPtch1+/ fetal liver cells by injecting
these mice with 5-fluorouracil (5-FU) (150 mg/kg). Short-term re-
generation capacity was significantly reduced in bone marrow
lacking Smo. Ten days after 5-FU injection, the number of
Ly5.2-positive cells in B6-Ly5.1 Smo/ mice was 70% lower
than in B6-Ly5.1 Smo+/+ mice, indicating a role of the Hh signal-
ing pathway in short-term repopulating HSCs (Figure 3F). As de-
scribed previously (Trowbridge et al., 2006), B6-Ly5.1 Ptch1+/
mice displayed enhanced short-term regeneration potential after
5-FU treatment as compared to B6-Ly5.1 Ptch1 or Smo WT
mice, indicating that in regular hematopoiesis, activation of the
Hh signaling pathway enhances the regeneration potential of
short-term repopulating HSCs. Similar results were obtained in
a retransplantation experiment (Figure S4). Interestingly, 40
days after 5-FU treatment, no significant differences remained
in the numbers of Ly5.2-positive cells between mice carrying
Smo/ versus Smo WT bone marrow, indicating that the long-
term repopulating HSCs were not affected by the loss of Smo
(Figure 3F). Therefore, pharmacological inhibition of Smo might
only affect short-term repopulating HSCs in regular hematopoi-
esis while long-term repopulating HSCs and long-term regener-
ation of hematopoiesis are not affected.
In contrast to a previous report (Trowbridge et al., 2006), we
could not detect an exhaustion of the long-term repopulating
cells in mice transplanted with Ptch1+/ fetal liver cells. After
5-FU injection, Ly5.2-positive cells remained elevated comparedc.
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(data not shown). Also, blood cell counts from 2-year-old
Ptch1+/ mice showed no difference in the number of peripheral
blood cells compared to Ptch1 WT mice, indicating that there is
no significant lack in the generation of differentiated hematopoi-
etic cells in these mice even after a long period of time (Figure S5).
Since the Hh signaling pathway is activated in Bcr-Abl-positive
cells by upregulation of the Smo receptor and not by downregu-
lation of Ptch1, we aimed to investigate the effect of Smo upre-
gulation on regular hematopoiesis. Therefore, we overexpressed
Figure 3. Self-Renewal Capacity of Short-
Term Repopulating Hematopoietic Stem
Cells and T Cell Development in Regular
Hematopoiesis Are Dependent on the
Status of Hedgehog Pathway Activation
(A) Schematic overview of replating and transplan-
tation experiments with embryonic liver cells.
(B) Genotyping for Smo/ mouse strain and
Ptch1+/ mouse strain. Relative transcript levels
for Gli1 in different mouse strains (mean of n = 3
mice per strain, ±SD) are shown.
(C) Replating assay (P2) with embryonic liver cells.
Colonies were photographed 10 days after replat-
ing. Scale bars = 1 mm.
(D) Number of Ly5.2-positive white blood cells in
peripheral blood after transplantation into irradi-
ated B6-Ly5.1 mice (0–13 weeks after transplan-
tation).
(E) Cell type distribution in peripheral blood within
the Ly5.2-positive population 10 weeks after
transplantation.
(F) Regeneration of Ly5.2-positive cells in periph-
eral blood 10 and 40 days after 5-fluorouracil
(5-FU) injection (150 mg/kg). Mean of n = 3 mice
per group, ±SD.
a GFP control vector, Smo WT-GFP, or
the activated mutant Smo W535E-GFP
in the bone marrow of 5-FU-pretreated
mice using a pMSCV-based IRES-GFP
vector system. Bone marrow cells over-
expressing Smo WT or Smo W535E had
significantly elevated Gli1 levels com-
pared to control bone marrow cells
(Figure 4A). Irradiated donor mice were
transplanted with 10% GFP-positive
bone marrow cells mixed with 90%
GFP-negative uninfected bone marrow
cells, and reconstitution of hematopoiesis was monitored by de-
termining blood cell counts and the fraction of GFP-positive cells
in the peripheral blood. The percentage of GFP-positive cells in
mice transplanted with bone marrow expressing the GFP control
vector remained constant at 10%–12% throughout the experi-
ment. In contrast, recipients of Smo WT- or Smo W535E-in-
fected bone marrow displayed a significant increase in the num-
ber of GFP-positive cells for more than 1 year (Figure 4B). The
maximum fraction of GFP-positive cells observed in these
mice was 30%. There were no significant differences in the
Figure 4. Overexpression of Smo in Bone
Marrow
(A) Relative Gli1 transcript levels measured by
TaqMan PCR in bone marrow infected with
pMSCV control, Smo-GFP, or Smo W535E-GFP
vector. n = 3, ±SD.
(B) Percentage of GFP-positive cells in peripheral
blood of mice transplanted with bone marrow ini-
tially containing 10% GFP-positive cells, 10%
Smo-GFP-positive cells, or 10% Smo W535E-
GFP-positive cells over a period of 60 weeks.Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc. 243
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population compared to the GFP-negative population, indicating
that all lineages were impacted to a similar degree. These data
indicate that Smo overexpression, similar to loss of Ptch1, can
induce Hh pathway activation and lead to the expansion of the
Smo-positive HSC pool. We therefore hypothesized that upregu-
lation of Smo in Bcr-Abl-positive cells might be one of the mech-
anisms by which Bcr-Abl-positive LSCs expand during the
chronic phase of the disease.
Loss of Smo Inhibits Expansion of Bcr-Abl-Positive
Leukemic Stem Cells in Mice and Abrogates
Retransplantability of the Disease
To further validate this hypothesis, we overexpressed Bcr-Abl in
Smo/, Smo+/, Smo+/+, Ptch1+/+, and Ptch1+/ embryonic
liver cells using a pMSCV/Bcr-Abl/IRES-GFP retroviral vector.
The infection rate was between 3% and 4%, and no difference
in the infection rate was observed between fetal liver stem cells
isolated from the various mouse strains. Fetal liver cells were
then transplanted into lethally irradiated C57BL/6 mice. GFP-
positive cells and blood cell counts were measured 20 days after
transplantation. Mice transplanted with Ptch1+//Bcr-Abl/GFP
fetal liver cells showed 3-fold higher numbers of Bcr-Abl/GFP-
positive cells than mice transplanted with Ptch1 WT or Smo
WT fetal liver cells infected with pMSCV/Bcr-Abl/GFP. In con-
Figure 5. Loss of Smo Inhibits Expansion of
Bcr-Abl-Positive Leukemic Stem Cells in
Mice
(A) Schematic overview of transplantation (Tx)
experiments with overexpression of the Bcr-Abl
oncogene.
(B) Number of Bcr-Abl-positive cells in peripheral
blood of transplanted mice 20 days after trans-
plantation. n = 3, ±SD.
(C) Spleen weight of transplanted mice 28 days
after transplantation. n = 3, ±SD.
(D) Survival of mice transplanted with Bcr-Abl-
infected fetal liver cells.
(E) Flow cytometric analysis of B220 and Gr-1
expression in bone marrow of leukemic mice.
(F) Survival of mice retransplanted with 2 3 105
Bcr-Abl (GFP)-positive bone marrow cells from
the indicated genotypes.
trast, Smo//Bcr-Abl/GFP-positive cells
had not expanded at all during this time
span, and the percentage of the GFP-
positive fraction had even dropped below
the original infection rate (Figure 5B).
Next, spleen weights were compared on
day 28 after transplantation (n = 3 mice
per group). All mice transplanted with
Ptch1+/, Ptch1WT, SmoWT, orSmo+//
Bcr-Abl/GFP fetal liver cells had a greater
than 40% increase in spleen weight, re-
flecting the onset of a leukemic disease.
In contrast, mice transplanted with
Smo//Bcr-Abl/GFP embryonic liver
cells had normal spleen weight (between
90 and 110 mg), indicating that Smo is important for the expan-
sion of Bcr-Abl-positive cells (Figure 5C). Finally, the remaining
mice from each group were monitored for onset of disease and
disease phenotype. All mice transplanted with Ptch1+/ embry-
onic liver cells developed a lethal leukemic disease within 38
days after transplantation. Recipients of WT or Smo+/ fetal liver
cells (Figure 5D) developed disease with slightly longer latency.
Phenotypic analysis of the leukemias developed in diseased
mice showed that animals transplanted with Ptch1+/– fetal liver
cells were more likely to develop a lymphoid disease phenotype
(70%), while mice transplanted with Smo+/ fetal liver cells were
more likely to develop a myeloid disease phenotype (70%)
(Figure 5E). In sharp contrast, only 60% of the mice transplanted
with Bcr-Abl-infected Smo/ fetal liver cells developed any le-
thal disease. The latency to onset of the disease was increased
to more than 3 months, and the disease was characterized by in-
creased spleen weight and infiltration of the bone marrow, but
surprisingly, no increase in white blood cell counts was seen in
the peripheral blood (data not shown). Remarkably, 40% of the
Smo//Bcr-Abl/GFP-transplanted mice had not developed any
signs of disease even 12 months after transplantation.
To further investigate the importance of activation of the Hh
signaling pathway for the LSC population, we collected bone
marrow and spleen cells from the diseased mice and retrans-
planted the cells into lethally irradiated secondary recipients.244 Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc.
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2 3 106 bone marrow cells from one healthy donor and two CML patients were seeded in long-term culture-initiating cell (LTC-IC) medium onto irradiated M2-
10B4 cells and treated with DMSO, cyclopamine (5 mM), nilotinib (0.5 mM), or a combination of both. Compound-containing medium was removed after 7 days,
and cells were cultured for 4 more weeks in LTC-IC medium before methylcellulose assays were performed. Numbers of colonies were counted after 20 days.
Numbers of LTC-IC-derived colony-forming units (cfu) from the healthy donor (A) versus CML patient 1 (B) and a CML patient with T315I mutation (C) are shown.
Mean of three independent experiments, ±SD.All secondary recipients from mice transplanted with 2 3 105
Bcr-Abl-positive Ptch1+/+, Ptch1+/, Smo+/+, or Smo+/ cells de-
veloped leukemias within 2 months after retransplantation, while
none of the mice transplanted with Bcr-Abl-positive Smo/
cells developed signs of disease over a 9 month observation pe-
riod (Figure 5F). Therefore, our results indicate that expansion of
Bcr-Abl-positive LSCs and the maintenance of self-renewal
properties in this population are dependent on intact and
activated Hh signaling.
Effects of a Combination of Abl and Smo Inhibitors
In Vitro and In Vivo
To investigate whether Hh pathway inhibition might be beneficial
in the treatment of CML and the elimination of self-renewing
LSCs, we examined the effect of a combination of Abl and
Smo inhibitors on the maintenance of long-term repopulating
cells from bone marrow of CML patients or healthy donors
in vitro (Figure 6). Long-term culture-initiating cell (LTC-IC) as-
says were performed for 5 weeks, including a 1 week treatment
of the cultures with DMSO, cyclopamine (5 mM), nilotinib
(0.5 mM), or a combination of cyclopamine and nilotinib for the
first week. After 5 weeks, adherent and floating cells were plated
on methylcellulose, and colonies were counted after 20 days.
The number of LTC-IC-derived colony-forming units (cfu) per
2 3 106 bone marrow cells was increased 1.42-fold in the CML
patient compared to the healthy donor (1356 in CML patient
versus 958 in healthy donor). Smo inhibition for 1 week in the
LTC-IC assay reduced the number of cfu obtained from the
CML patient by about 54% (620 cfu) while nilotinib reduced the
number of cfu by 29% (951 cfu) (Figure 6B). A combination of
both reduced the number of cfu by more than 80%, indicating
that the combination of Smo and Abl inhibitors might be an effec-Cative combination treatment for the reduction of CML stem cells.
Similar results were obtained using bone marrow from two addi-
tional CML patients (patient 2 with Bcr-Abl WT [Figure S6]; pa-
tient 3 with Bcr-Abl T315I [Figure 6C]), indicating that LSCs
with mutatedBcr-Abl are also sensitive to Smo inhibition. The ef-
fect of Smo inhibition on the number of LTC-IC-derived colonies
was dose dependent (Figure S6). In contrast, cyclopamine and
nilotinib treatment of LTC-IC cultures from a healthy donor re-
duced the number of colonies by only 25% (958 cfu with
DMSO/713 with cyclopamine + nilotinib). This effect was mainly
due to nilotinib pretreatment (reduction of cfu = 23%; 730 cfu);
Smo inhibition alone reduced the colony numbers by less than
10% (870 cfu) (Figure 6A). The effect seen with nilotinib treatment
might be due to inhibition of Kit, which besides Abl is a major tar-
get of this inhibitor.
To further validate the effect of Smo and Abl inhibitor combina-
tions on the reduction of LSCs in vivo, we induced a CML-like
syndrome in mice by transplantation of Bcr-Abl/GFP-expressing
bone marrow into irradiated recipient mice. Mice were treated
with cyclopamine, nilotinib, a combination of both, or vehicle
control starting 7 days after transplantation. Nilotinib was chosen
over imatinib due to its 20-fold stronger Abl kinase inhibition
(Kantarjian et al., 2006) and its superior pharmacological proper-
ties in mice (Weisberg et al., 2005). The compound was dosed at
50 mg/kg/day, a dose shown to lead to sustained inhibition of Abl
kinase over 24 hr and therefore assumed to be optimal. Due to
the sensitization of mice by irradiation to the side effects of
cyclopamine, including diarrhea and seizures, we had to use
a lower than optimal dose of 25 mg/kg bid. Importantly, Gli1
levels in the bone marrow of Bcr-Abl-positive mice dosed with
25 mg/kg/bid of cyclopamine for 7 days were reduced by 50%
compared to vehicle-treated mice, but the Gli1 levels werencer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc. 245
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Cyclopamine Reduces the Number of Bcr-
Abl-Positive Colony-Forming Cells in Bone
Marrow and Enhances Time to Relapse
after End of Treatment
(A) Bone marrow transplantation model with start
of treatment 7 days after transplantation with
either nilotinib alone (50 mg/kg/day) or a combina-
tion of nilotinib (50 mg/kg/day) and cyclopamine
(25 mg/kg/bid).
(B) Relative amount of GFP-positive bone marrow
colonies in one femur in Bcr-Abl-positive mice
treated with either nilotinib alone or a combination
of nilotinib and cyclopamine. n = 3 per treatment
group, ±SD.
(C) Spleen and liver weights 8 days after end of
treatment. n = 3 per treatment group, ±SD.
(D) Survival in days after end of treatment with
either nilotinib alone or a combination of nilotinib
and cyclopamine.still elevated about 3-fold compared to mice not expressing Bcr-
Abl (Figure S7), indicating that the level of inhibition of the Hh
pathway achieved with this dose was incomplete.
After 6 days of treatment, bone marrow was harvested and the
percentage of Bcr-Abl/GFP-positive LSCs (Kit+Sca+) in the Lin
population was assessed using flow cytometry. Despite using
a suboptimal dose, cyclopamine treatment reduced the number
of Bcr-Abl-positive LSCs (LinGFP+Sca+Kit+) by about 55%,
nilotinib by 44%, and a combination of both by 82%, indicating
a combination of both inhibitors as an effective strategy to
reduce LSCs in Bcr-Abl-positive mice (Figure S8).
In addition, cyclopamine treatment of Bcr-Abl-positive mice
starting at day 7 after transplantation increased survival of the
mice by about 4 days (average survival: vehicle 13 days, cyclo-
pamine 17 days) (Figure S7) but did not completely suppress
the disease. As indicated by our transplantation experiments us-
ing Bcr/Abl-positive Smo/ fetal liver cells, loss of Smo does not
necessarily affect all disease-propagating Bcr-Abl-positive
progenitor populations but was able to completely suppress
retransplantability of the disease, indicating a loss of the LSCs.
In an additional experiment, we attempted to further validate
the cooperative effect of Abl and Smo inhibitors on eradication
of progenitors and LSCs in vivo. We treated mice carrying Bcr-
Abl-transduced bone marrow with either nilotinib alone (50 mg/
kg/day) or a combination of nilotinib (50 mg/kg/day) and the
Smo antagonist cyclopamine (25 mg/kg bid). Treatment was
started 7 days after transplantation and was continued for a total
of 14 days. At the end of the treatment, three mice in each group
were sacrificed, bone marrow from one femur per mouse was
isolated, and cells were plated in methylcellulose without addi-
tion of cytokines to detect colony formation of Bcr-Abl-positive
cells (Figure 7A). The average number of colonies detected in
mice treated with the combination of nilotinib and cyclopamine
(N+C) was reduced more than 40% compared to the nilotinib-
only (N) treatment group, indicating that addition of cyclopamine
leads to an additional reduction of the number of Bcr-Abl-posi-
tive cfu (Figure 7B). Peripheral blood cell counts and spleen
and liver weights were normal at that time point, and the number
of GFP-positive cells was below 5% for both treatment groups.
Eight days after the end of treatment, an additional three mice246 Cancer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Incper group were sacrificed and investigated for signs of relapse
by comparing liver and spleen weights. We found increased liver
and spleen weights in all mice compared to normal mice, but
mice treated with N alone had more than double the average
spleen size (N, 1090 mg; N+C, 410 mg) and a significantly higher
liver weight (N, 2550 mg; N+C, 1430 mg) than mice treated with
the N+C combination (Figure 7C). The five remaining mice in
each group were monitored for signs of disease and sacrificed
when moribund. The average survival after end of treatment
was 8 days in the N group versus 24 days in the N+C group
(Figure 7D), indicating that the combination of Abl and Smo in-
hibitors reduced the number of repopulating cells responsible
for relapse more than Abl inhibition by itself. This indicates that
a combination of Smo and Abl inhibitors might be an effective
treatment strategy to eradicate progenitors and LSCs in
Bcr-Abl-positive disease.
DISCUSSION
CML is one of the best understood malignancies due to the fact
that a single oncogene, Bcr-Abl, is the cause of more than 95%
of CMLs. The treatment of these patients with the Abl inhibitor
imatinib leads to response rates of greater than 95%, and
most patients experience few side effects and can stay on the
medication for years (Druker et al., 2006). Despite this great suc-
cess, there are still drawbacks that need to be addressed. Above
all, 17% of patients develop resistance to the therapy partially
due to preexisting point mutations in Bcr-Abl-positive LSCs,
which expand over time and cause relapse of disease. Further-
more, it is not yet clear whether responsive patients can ever
stop taking imatinib, as there is evidence that Bcr-Abl-positive
LSCs remain present in the patient’s bone marrow even after
years of therapy and can cause relapse of disease. Therefore,
it is necessary to define targets in Bcr-Abl-positive LSCs that
might be candidates for new treatment options.
Our study reveals that one candidate could be Smo. Smo ap-
pears to be specifically upregulated in Bcr-Abl-positive hemato-
poietic cells and LSCs versus in regular hematopoiesis and
HSCs. Loss of Smo in regular hematopoiesis had no significant
impact on the regeneration of hematopoiesis in general besides.
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pact the short-term repopulating HSCs or the acute expansion of
stem cells after 5-FU treatment or retransplantation, while long-
term reconstitution of the bone marrow was not affected. These
findings are of significant importance, as several pharmaceutical
companies develop Smo inhibitors for the treatment of solid tu-
mors such as medulloblastomas or basal cell carcinomas. The
finding that long-term repopulating cells in the bone marrow
are independent of Hedgehog opens new options for the sys-
temic application of these drugs and might allow broader clinical
use of Smo inhibitors. On the other hand, the loss of CD8+ T cells
in Smo/ bone marrow indicates that Smo inhibition might
cause partial immunosuppression in treated patients, and further
studies will be needed to evaluate whether preexisting CD8+
T cells will be affected by Smo inhibition and whether CD8+
T cell suppression is a transient or permanent effect caused by
Smo inhibitors. Furthermore, the impact of Smo on the short-
term repopulating HSCs indicates that a combination of Smo
inhibitors with generally cytotoxic and hematotoxic chemothera-
peutics might induce prolonged neutropenias, anemias, and/or
thrombocytopenias due to delayed bone marrow regeneration,
and it might be more favorable to combine Smo inhibitors with
target-specific biological agents or small-molecule inhibitors.
In contrast to regular hematopoiesis, lack of Smo in Bcr-Abl-
positive hematopoiesis effectively reduced the development of
Bcr-Abl-positive leukemias in mice and abolished retransplant-
ability of the disease, indicating a loss of the Bcr-Abl-positive
LSC pool. These findings were corroborated using LTC-IC cul-
tures from CML patients, wherein Smo inhibition significantly re-
duced the number of long-term repopulating LSCs independent
of Bcr-Abl mutation status. Furthermore, combination treatment
of Bcr-Abl-positive mice with cyclopamine (a Smo inhibitor) and
nilotinib (an Abl inhibitor) induced reduction of LSCs and
enhanced time to relapse 3-fold after the end of treatment com-
pared to nilotinib treatment alone. Our results indicate that Smo
might be a specific target in Bcr-Abl-positive LSCs, while it is not
essential for the long-term regeneration potential of regular
HSCs. Furthermore, the effect of Smo inhibition on the LSC
pool in CML is independent of Bcr-Abl mutation status, which in-
dicates that Smo inhibition might help to prevent the expansion
of imatinib-resistant LSCs during treatment. Hence, combina-
tions of Abl and Smo inhibitors might offer a new treatment strat-
egy in CML and might help to effectively eliminate the Bcr-Abl-
positive LSC pool.
EXPERIMENTAL PROCEDURES
Mouse Experiments
Ptch1+/ mice (The Jackson Laboratory), Smo+/ mice (Deltagen), C57BL/6
mice (The Jackson Laboratory), and B6-Pep3b-Ly5.1 (Pep) mice were main-
tained and genotyped as described by the vendor. For bone marrow trans-
plantation experiments, C57BL/6 males were injected intraperitoneally with
5-FU (150 mg/kg), and mice were sacrificed 4 days later. Bone marrow mono-
nuclear cells were flushed from the leg bones, red blood cells were lysed with
ammonium chloride, and bone marrow cells were then cultivated in DMEM
containing 10% FBS, SCF, IL-6, and IL-3.
For compound treatment experiments, cells were infected with a pMSCV/
Bcr-Abl/IRES-GFP retrovirus. 5 3 105 mononuclear cells were transplanted
into lethally irradiated C57BL/6 mice. Treatment with nilotinib (50 mg/kg bid
orally; Tasigna, Novartis [Basel]) and cyclopamine (25 mg/kg bid subcutane-
ously; Novartis [Cambridge]) started on day 7 after transplantation forCa14 days. At the end of treatment, three mice were sacrificed per group, and
bone marrow cells from one femur per mouse were used for colony assays
(methylcellulose) without cytokines. Seven days after the end of treatment,
another seven mice were sacrificed to compare spleen weights between the
treatment groups. The five remaining mice per group were monitored for signs
of disease and time to relapse.
For further bone marrow transplantation experiments with pMSCV/IRES-
GFP control vector, pMSCV/Smo/IRES-GFP vector, and pMSCV/Smo
W535E/IRES-GFP vector, we used the same methods as described above.
For transplantation experiments with fetal liver cells from Ptch1+/, Ptch1
WT, Smo WT, Smo+/, and Smo/ mice, we used embryos at day 14.5 of
the gestation period. Embryos were chilled on ice and decapitated. The em-
bryonic liver was extracted, and liver cells were filtered through a cell strainer
(BD Biosciences). Embryonic liver cells were either directly transplanted into
sublethally irradiated B6-Pep3b-Ly5.1 (Pep) mice for repopulation experi-
ments or cultured in stimulation medium and then infected with a pMSCV/
Bcr-Abl/IRES-GFP retrovirus. Number of GFP-positive cells was determined
24 hr after infection by flow cytometry, and we tried to keep the infection
rate between 4% and 6% to evaluate the expansion of the Bcr-Abl-positive
cells. Fetal liver cells were then transplanted into lethally irradiated recipients.
Disease development was monitored by weekly weight measurements,
biweekly blood cell counts, and detection of GFP-positive cells in the periph-
eral blood. For retransplantation experiments, we used 23 105 Bcr-Abl/GFP-
positive cells or 5 3 105 Ly5.2-positive bone marrow cells.
All animal experiments were approved by the Institutional Animal Care and
Use Committee at the Genomics Institute of the Novartis Research Foundation
and were performed in accordance with the US National Institutes of Health
Statement of Compliance with Standards for Humane Care and Use of Labo-
ratory Animals.
Cell Culture Experiments
Bone marrow cells from diseased mice were cultured in DMEM containing
10% FBS (GIBCO), SCF (RDI), IL-3, and IL-6 (R&D Systems). For in vitro treat-
ment experiments, we seeded 4 3 106 bone marrow or spleen cells into one
well of a six-well plate. KAAD-cyclopamine (Toronto Research Chemicals)
was dissolved as 10003 stock in DMSO. After 72 hr of treatment, cells were
plated in methylcellulose medium containing SCF, IL-6, IL-3, and insulin
from StemCell Technologies (M3434) according to the manufacturer’s instruc-
tion. Colonies were counted 5 days and 10 days after plating. After 12 days,
cells were diluted from the plates, washed in PBS, and then either stained
for analysis of different cell types or replated into a second or third plating
round.
LTC-IC Assays
23 106 bone marrow cells from healthy donors or CML patients were cultured
with irradiated M2-10B4 fibroblasts in MyeloCult medium (StemCell Technol-
ogies H5100) with hydrocortisone according to the manufacturer’s instruc-
tions. In the first week, cyclopamine (5 mM), nilotinib (0.5 mM), a combination
of both, or DMSO was added to the culture. Medium containing the com-
pounds was replaced after 7 days. After 5 weeks of culture, adherent and float-
ing cells were harvested and 53 104 cells were plated into MethoCult medium
(StemCell Technologies H4435). Numbers of colonies derived from long-term
culture-initiating cells (LTC-ICs) were counted after 20 days.
Immunohistochemistry
Mouse tissues were fixed for at least 24 hr in formalin, and paraffin-embedded
tissues were generated after standard procedures. Human tissues were a kind
gift from A. Schmitt-Gra¨ff (University of Freiburg, Germany). Single-color DAB-
immunoperoxidase staining was performed on paraffin-embedded sections
using antibodies to Gli1 (N-16, Santa Cruz Biotechnology), Smo (H-300, Santa
Cruz Biotechnology), and Hh (H-160, Santa Cruz Biotechnology) according to
the manufacturer’s recommendation.
RT-PCR and Quantitative PCR
RNA was extracted from CD34+ cells from healthy donors or CML patients in
the chronic or blast crisis phase of the disease (Table S1). RNA extraction was
performed using a QIAGEN RNA extraction kit according to the manufacturer’s
recommendation. Quantitative PCR was assessed by TaqMan PCR usingncer Cell 14, 238–249, September 9, 2008 ª2008 Elsevier Inc. 247
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gen). Primers and probes were obtained from Applied Biosystems (see
Supplemental Experimental Procedures).
Cell Staining and Sorting
Flow cytometry stainings for analysis of hematological cell types were per-
formed using the antibodies Sca-PE and Kit-APC and the lineage markers
CD3, Gr-1, CD11b, CD19, Ter119 all PE-Cy7-pos., CD4-PE, and CD8-APC
from BD Pharmingen according to the manufacturer’s instructions. For cell-cy-
cle analysis of stem cells, cells were treated with cyclopamine for 48 hr and
then stained with lineage markers, Kit-APC, and Sca-PE. Stained bone mar-
row was fixed in 2% formalin, and cells were permeabilized with 70% chilled
ethanol for at least 1 hr and then treated with propidium iodide (5 mg/ml) for
at least 30 min. Cells were analyzed using a flow cytometer (Coulter). Annexin
staining was performed after incubation of mixed bone marrow with cyclo-
pamine for 24, 48, and 72 hr. Cells were stained with annexin-PE antibody
and 7-AAD (BD Biosciences) according to the manufacturer’s instructions.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, eight
figures, and two tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/14/3/238/DC1/.
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